QA108 Phase III Study in Subjects With Intermediate AMD

NCT ID: NCT07189169

Last Updated: 2025-09-23

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 400 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-07-08
• Study Completion Date: 2027-06-30

Brief Summary

This is a phase III randomized, double-masked, placebo-controlled, multicenter study. To evaluate the efficacy and safety of QA108 granules in the treatment of intermediate age-related macular degeneration.

Conditions

Intermediate Age-Related Macular Degeneration

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

QA108 granules, 7.5 g/bag,2 bags/time, BID

Group Type: EXPERIMENTAL

QA108 granules

Intervention Type: DRUG

Take the medication as required for 24 weeks

QA108 granule simulants, 7.5 g/bag,2 bags/time, BID

Group Type: PLACEBO_COMPARATOR

QA108 granules placebo

Intervention Type: DRUG

Take the medication as required for 24 weeks

Interventions

QA108 granules

Take the medication as required for 24 weeks

Intervention Type: DRUG

QA108 granules placebo

Take the medication as required for 24 weeks

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. The study eye meets the Western medicine diagnostic criteria for intermediate age-related macular degeneration;

2. Presence of at least one large drusen (diameter ≥125 μm) in the macular area of the fundus;

3. Consistent with the TCM diagnosis of type of Yang-hyperactivity due to Yin-deficiency;

4. Age 45-85 years (inclusive), regardless of gender;

5. The study eye has a BCVA of 88-34 letters (using the ETDRS chart, inclusive of threshold values), equivalent to a Snellen visual acuity of 20/20 to 20/200 (inclusive);

6. Voluntary participation in this clinical trial, with informed consent provided and an informed consent form signed

Exclusion Criteria

1. The study eye is with concomitant eye disorders that may interfere with the observation of the trial as judged by the investigator, including pathological myopia, glaucoma, diabetic retinopathy, retinal vein occlusion, uveitis, retinal detachment, optic neuropathy (optic neuritis, atrophy, papilledema), and macular hole;

2. The study eye has an intraocular pressure (IOP) ≥ 25 mmHg;

3. Presence of geographic atrophy (GA) involving the foveal center in the study eye;

4. Previous ophthalmic surgery in the study eye: vitrectomy, macular translocation;

5. Aphakia (except pseudophakia) or posterior capsule rupture (except YAG laser posterior capsulotomy after IOL implantation at more than 1 month prior to screening) of the study eye;

6. Any intraocular surgery (excluding intravitreal injections) that may affect trial observations or imaging in the study eye within 3 months;

7. Cataract in the study eye that interferes with fundus examination or imaging;

8. Treatments received in the study eye within 3 months prior to screening, including macular laser photocoagulation and micropulse laser therapy;

9. The patient received relevant TCM treatment within 1 month prior to screening;

10. Active ocular infection in either eye that affects fundus examination or imaging;

11. The non-study eye has a BCVA of less than 19 ETDRS letters (not inclusive);

12. Known allergy to the therapeutic or diagnostic drug used in the study protocol, including the single drug components in the study drugs;

13. Poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg after regular use of antihypertensive drugs);

14. Platelet count ≤100×10⁹/L (unless follow-up results are normal), or any of the following exceeding 1.5 times the upper limit of normal (ULN): total bilirubin (TBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), or serum creatinine (Cr);

15. Pregnant women, women who are breastfeeding, those who plan for pregnancy in the next six months, or those who are unwilling to take effective birth controls during the study course and until six months after drug withdrawal;

16. Any uncontrollable clinical disorder prior to the start of treatment, such as severe psychiatric, neurological, respiratory, immunological, hematological, and cardiac system diseases, and malignant tumors;

17. Subjects who have participated in other clinical trials within 3 months prior to this trial;

18. Patients who are unsuitable for participating at the discretion of the investigator.

• Minimum Eligible Age: 45 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Smilebiotek Zhuhai Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Beijing Hospital

Beijing, , China

Site Status: RECRUITING

Countries

China

Central Contacts

Hong Dai

Role: CONTACT

Dai-hong@x263.net

010-85132171

Facility Contacts

hong Dai

Role: primary

Dai-hong@x263.net

010-85132171

Other Identifiers

QA108-III

Identifier Type: -

Identifier Source: org_study_id